Ayala Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	2018 - 2002
Net Income	-48.07	-48.07	-14.36	-17.86	-26.47	-17.79	Upgrade
Depreciation & Amortization	0.31	0.37	0.31	0.99	1.98	0.15	Upgrade
Share-Based Compensation	0.09	1.22	2.24	2.68	1.57	0.73	Upgrade
Other Operating Activities	26.75	17	-3.48	-1.25	0.98	1.97	Upgrade
Operating Cash Flow	-20.92	-29.49	-15.28	-15.44	-21.94	-14.95	Upgrade
Capital Expenditures	0	0	-0.2	-0.46	-0.75	-1.33	Upgrade
Acquisitions	0	1.91	0.04	0.45	0	0.08	Upgrade
Change in Investments	-	-	-	-	-0.23	-	Upgrade
Other Investing Activities	0.73	4.04	-	-	0.23	-0.33	Upgrade
Investing Cash Flow	0.73	5.95	-0.17	-0.01	-0.75	-1.58	Upgrade
Common Stock Issued	21.2	20	4.31	28.12	15.5	24.57	Upgrade
Share Repurchases	0	0	-5.25	0	0	0	Upgrade
Other Financing Activities	6	6	-10.52	3.77	0.01	-17.5	Upgrade
Financing Cash Flow	27.2	26	-0.96	31.89	15.5	7.08	Upgrade
Net Cash Flow	2.49	2.49	-16.41	16.44	-7.19	-9.46	Upgrade
Free Cash Flow	-20.92	-29.49	-15.49	-15.9	-22.69	-16.28	Upgrade
Free Cash Flow Margin	-160953.85%	-226807.69%	-6194.00%	-490.71%	-8967.59%	-697.51%	Upgrade
Free Cash Flow Per Share	-3.48	-4.90	-8.51	-9.85	-29.75	-85.64	Upgrade

Sources: The data provider is Financial Modeling Prep and the numbers are sourced from SEC filings.